NCT05668806

RWE Study in the Treatment of Cervical Lesions of Various Etiology

Study of Real-world Evidence in Patients Treated With Cerviron Vaginal Ovules in the Treatment of Cervical Lesions of Various Etiology

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 345 (actual)
• Sponsor: Perfect Care Distribution · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: —

Summary

The aim of the study was to assess the post-market performance and tolerability of Cerviron® ovules in the treatment and management of cervical lesions of different etiologies. The study included clinical data related to aspect of lesions performed during routine colposcopy exams, the degree of re-epithelialization of the cervical mucosa, vaginal pH, pain level, and vaginal bleeding level.

Detailed description

This study is an observational, post-marketing study conducted between May-July 2021. The aim of the study was to assess the post-market performance and tolerability of Cerviron® ovules in the treatment and management of cervical lesions of different etiologies. The secondary objective of this clinical investigation is the assessment of performance of the medical device by clinical exam and patients' degree of satisfaction related to the use of the medical device. The study population included 345 participants aged 20-70 years with either a cervical lesion under treatment or with recent surgical removal of a cervical lesion.

Conditions

• Cervical Lesion
• Vaginal Bleeding

Interventions

Type	Name	Description
DEVICE	Cerviron	Cerviron® is an invasive medical device of short-term use classified under annex VIII of the European Regulation 2017/745 as class IIb according to Rule 21 (devices composed of substances or of combinations of substances to be introduced into the human body via a body orifice or applied to the skin and absorbed by or locally dispersed in the human body). Cerviron® has a complex composition consisting of three topical pharmaceutical products - hexylresorcinol, collagen and bismuth subgallate - and four phytotherapeutic extracts - Calendula officinalis, Hydrastis canadensis, Thymus vulgaris extract and Curcuma longa. The Instructions for use specify its field of use as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora and of cervical lesions of mechanical origin.

Timeline

• Start date: 2021-05-20
• Primary completion: 2021-07-31
• Completion: 2021-07-31
• First posted: 2022-12-30
• Last updated: 2022-12-30

Locations

15 sites across 1 country: Romania